Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact

E2F8 keeps liver cancer at bay

Members of the E2F family of transcription factors are key regulators of cell cycle-dependent gene expression. Dysregulation of E2F-mediated gene expression has been implicated in the development of several types of cancer, including hepatocellular carcinoma (HCC). However, the molecular mechanisms by which E2F-mediated gene expression programs influence tumor development remain enigmatic. The function of E2F8, an atypical repressor that is highly expressed in HCC, has been explored in cell lines or in other contexts, but its role in cancer development in vivo has not yet been examined. A team led by Alain de Bruin and Gustavo Leone of Utrecht University and the Ohio State University, respectively, now demonstrates that E2F8 functions in the developing liver to suppress HCC. Using mice with a liver-specific knockout of E2f8, the authors determined that E2F8 suppresses both carcinogen-driven and spontaneous tumors of the liver in a cell autonomous manner. Further investigation using temporal-specific ablation strategies, demonstrated that this E2F8 tumor suppression occurs within a relatively short window of time during early postnatal liver development. The multiple functions of E2F8 in embryonic development, hepatocyte polyploidization, and tumor suppression were shown to depend on the DNA binding domain, a module that is essential for regulating gene expression. Consequently, the authors identified E2F8 target genes and found that increased expression of these genes, which would occur in the absence of E2F8 repression, is associated with human HCC. In sum, the data indicate that E2F8-mediated repression of E2F transcriptional output during liver development is a key regulator of HCC development later in life. The accompanying images show livers (top) and H&E-stained liver sections (bottom) from 9-month old mice that were treated with the liver-specific carcinogen diethylnitrosamine. The E2f8 genomic locus was either unperturbed (left panels) or ablated (right panels) during early postnatal development. Note the presence of multifocal tumors in the absence of E2F8.

Published July 25, 2016, by Brian P. Head

Scientific Show StopperOncology

Related articles

E2f8 mediates tumor suppression in postnatal liver development
Lindsey N. Kent, … , Alain de Bruin, Gustavo Leone
Lindsey N. Kent, … , Alain de Bruin, Gustavo Leone
Published July 25, 2016
Citation Information: J Clin Invest. 2016;126(8):2955-2969. https://doi.org/10.1172/JCI85506.
View: Text | PDF
Research Article Oncology

E2f8 mediates tumor suppression in postnatal liver development

  • Text
  • PDF
Abstract

E2F-mediated transcriptional repression of cell cycle–dependent gene expression is critical for the control of cellular proliferation, survival, and development. E2F signaling also interacts with transcriptional programs that are downstream of genetic predictors for cancer development, including hepatocellular carcinoma (HCC). Here, we evaluated the function of the atypical repressor genes E2f7 and E2f8 in adult liver physiology. Using several loss-of-function alleles in mice, we determined that combined deletion of E2f7 and E2f8 in hepatocytes leads to HCC. Temporal-specific ablation strategies revealed that E2f8’s tumor suppressor role is critical during the first 2 weeks of life, which correspond to a highly proliferative stage of postnatal liver development. Disruption of E2F8’s DNA binding activity phenocopied the effects of an E2f8 null allele and led to HCC. Finally, a profile of chromatin occupancy and gene expression in young and tumor-bearing mice identified a set of shared targets for E2F7 and E2F8 whose increased expression during early postnatal liver development is associated with HCC progression in mice. Increased expression of E2F8-specific target genes was also observed in human liver biopsies from HCC patients compared to healthy patients. In summary, these studies suggest that E2F8-mediated transcriptional repression is a critical tumor suppressor mechanism during postnatal liver development.

Authors

Lindsey N. Kent, Jessica B. Rakijas, Shusil K. Pandit, Bart Westendorp, Hui-Zi Chen, Justin T. Huntington, Xing Tang, Sooin Bae, Arunima Srivastava, Shantibhusan Senapati, Christopher Koivisto, Chelsea K. Martin, Maria C. Cuitino, Miguel Perez, Julian M. Clouse, Veda Chokshi, Neelam Shinde, Raleigh Kladney, Daokun Sun, Antonio Perez-Castro, Ramadhan B. Matondo, Sathidpak Nantasanti, Michal Mokry, Kun Huang, Raghu Machiraju, Soledad Fernandez, Thomas J. Rosol, Vincenzo Coppola, Kamal S. Pohar, James M. Pipas, Carl R. Schmidt, Alain de Bruin, Gustavo Leone

×
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts